Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)
The summary for the Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional): Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips are fast, sensitive, low cost and reasonably accurate. However, as there might not be testing strips for the new threats, the analysis must be performed via sensitive and sample agnostic methods.
Federal Grant Title: | Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education, Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DA-26-019 |
Type of Funding: | Grant |
CFDA Numbers: | 93.279 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | February 19th, 2025 |
Original Application Deadline: | February 19th, 2025 |
Posted Date: | November 4th, 2024 |
Creation Date: | November 4th, 2024 |
Archive Date: | March 27th, 2025 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | November 4th, 2024 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: See NOFO for further Eligibility Requirements.
- Link to Full Grant Announcement
- https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html
- Grant Announcement Contact
- NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R41 - Cl...
- • Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43 - Cl...
- • Limited Competition: NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinic...
- • NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial O...
- • Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleter...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
- • Alcohol Health Services Research (R01 Clinical Trial Optional)
- • Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
- • Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Re...
- • Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the...